BIOSGN logo

Biosergen AB (publ)OM:BIOSGN Stock Report

Market Cap SEK 12.4m
Share Price
n/a
1Y-90.5%
7D13.7%
1D6.0%
Portfolio Value
​
View

Biosergen AB (publ)

OM:BIOSGN Stock Report

Market Cap: SEK 12.4m

Biosergen (BIOSGN) Stock Overview

A biotech company, develops antifungal products. More details

BIOSGN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap (SEK12M)

Makes less than USD$1m in revenue (SEK0)

Highly volatile share price over the past 3 months compared to the Swedish market


BIOSGN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW499,106 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
499,106 investors already sharing narratives
View all narratives

Biosergen AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biosergen
Historical stock prices
Current Share PriceSEK 5.30
52 Week HighSEK 58.00
52 Week LowSEK 4.28
Beta-0.018
1 Month Change-40.45%
3 Month Change-51.82%
1 Year Change-90.50%
3 Year Change-94.85%
5 Year Change-99.27%
Change since IPO-99.25%

Recent News & Updates

Recent updates

Shareholder Returns

BIOSGNSE BiotechsSE Market
7D13.7%3.1%2.7%
1Y-90.5%31.6%12.9%

Return vs Industry: BIOSGN underperformed the Swedish Biotechs industry which returned 31.2% over the past year.

Return vs Market: BIOSGN underperformed the Swedish Market which returned 13.3% over the past year.

Price Volatility

Is BIOSGN's price volatile compared to industry and market?
BIOSGN volatility
BIOSGN Average Weekly Movement23.0%
Biotechs Industry Average Movement9.6%
Market Average Movement6.1%
10% most volatile stocks in SE Market12.8%
10% least volatile stocks in SE Market3.4%

Stable Share Price: BIOSGN's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: BIOSGN's weekly volatility has increased from 13% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20041Tine Olesenwww.biosergen.net

Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.

Biosergen AB (publ) Fundamentals Summary

How do Biosergen's earnings and revenue compare to its market cap?
BIOSGN fundamental statistics
Market capSEK 12.45m
Earnings (TTM)-SEK 38.01m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.3x
P/E Ratio

Is BIOSGN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIOSGN income statement (TTM)
RevenueSEK 0
Cost of RevenueSEK 0
Gross ProfitSEK 0
Other ExpensesSEK 38.01m
Earnings-SEK 38.01m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Aug 18, 2026

Earnings per share (EPS)-16.19
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BIOSGN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 02:55
End of Day Share Price 2026/07/06 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biosergen AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Herman KuntscherCarlsquare AB